|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Hepatitis B & C - Winning Battles But Not The War
Datamonitor, Dec 2004, Pages: 329
Introduction
According to the WHO, 350400 million are chronically infected with HBV and 170200 million with HCV. Although HBV vaccination and routine screening of donated blood has decreased incidence, the death toll resulting from chronic disease, cirrhosis and HCC is as high as one million per year (WHO, 2002). For HCV related conditions, this number will increase further over the next 1020 years.
Scope
Comprehensive overview of HBV and HCV epidemiology with comment on latest dynamics
Analysis of drug treatment choice per line therapy per region for both HBV and HCV
Discussion with key opinion leaders with regard to clinical and non-clinical attributes of therapy
Future outlook for new HBV and HCV therapies along with unmet needs assessment
Highlights
While diagnosis rates of HBV has remained flat since 2002, HCV diagnosis rates have increased 2-4 fold with highest growth in Japan.
Based on current estimates of prevalence, diagnosis and treatment current patient pools of between 1.8-2.0 million per disease.
To increase the treatment pool, manufacturers of hepatitis treatments can either tap into a substantial amount of unidentified cases or meet the needs of non-responder or difficult to treat patients.
Reasons to Purchase
Gain up-to-date understanding of current therapy usage and selection choices per region
Review current head-to-head competition between PEG-Intron and Pegasys per region
Justify internal unmet needs assessment per disease versus external viewpoint
Customers who bought this item also bought
Treatment Algorithms 2002: Hepatitis B and C
Treatment Algorithms 2002: Venous Thromboembolism Acute Therapy
BR HOLDINGS - World'Vest Base Dossier
Br Malls Participacoes Sa
Br. Holdings Corporation
Treatment Algorithms 2002: Alzheimer's Disease - Aricept: the physicians choice
Treatment Algorithms 2001: Schizophrenia - The Rise of Atypical Neuroleptics as the Physicians� Favorite
Commercial Perspectives: Pegylated Interferons - Leading the Way in HCV Therapy?
Treatment Algorithms 2002: Heart failure - managing chronic and acute patients
Treatment Algorithms 2001: Venous Thromboembolism - Prophylaxis
Diabetes: Opinion Leader Forum - Expert's Views and Perspectives on Diagnosis, Treatment, Product Performance, and Closing the Need Gap
Stakeholder Insight: Inflammatory Bowel Disease - Efficacy and Compliance Key to Maximizing Patient Share as Novel Biologics Wait in the Wings
|
|
|
|
